Genmab AS (GMAB)
21.21
-0.46
(-2.12%)
USD |
NASDAQ |
Nov 14, 16:00
21.21
0.00 (0.00%)
After-Hours: 18:33
Genmab Enterprise Value: 11.17B for Nov. 13, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2024 | 11.17B |
| November 12, 2024 | 11.68B |
| November 11, 2024 | 12.14B |
| November 08, 2024 | 12.07B |
| November 07, 2024 | 12.08B |
| November 06, 2024 | 11.59B |
| November 05, 2024 | 11.86B |
| November 04, 2024 | 11.87B |
| November 01, 2024 | 11.73B |
| October 31, 2024 | 11.58B |
| October 30, 2024 | 11.74B |
| October 29, 2024 | 12.09B |
| October 28, 2024 | 12.10B |
| October 25, 2024 | 12.09B |
| October 24, 2024 | 11.90B |
| October 23, 2024 | 11.84B |
| October 22, 2024 | 11.87B |
| October 21, 2024 | 11.87B |
| October 18, 2024 | 12.00B |
| October 17, 2024 | 11.99B |
| October 16, 2024 | 11.76B |
| October 15, 2024 | 12.13B |
| October 14, 2024 | 12.43B |
| October 11, 2024 | 12.35B |
| October 10, 2024 | 12.47B |
| Date | Value |
|---|---|
| October 09, 2024 | 12.43B |
| October 08, 2024 | 12.39B |
| October 07, 2024 | 12.29B |
| October 04, 2024 | 12.33B |
| October 03, 2024 | 12.27B |
| October 02, 2024 | 12.45B |
| October 01, 2024 | 12.74B |
| September 30, 2024 | 12.89B |
| September 27, 2024 | 13.19B |
| September 26, 2024 | 13.06B |
| September 25, 2024 | 12.87B |
| September 24, 2024 | 12.99B |
| September 23, 2024 | 13.07B |
| September 20, 2024 | 13.95B |
| September 19, 2024 | 14.56B |
| September 18, 2024 | 14.38B |
| September 17, 2024 | 14.53B |
| September 16, 2024 | 14.62B |
| September 13, 2024 | 14.82B |
| September 12, 2024 | 14.56B |
| September 11, 2024 | 14.84B |
| September 10, 2024 | 15.21B |
| September 09, 2024 | 15.18B |
| September 06, 2024 | 15.22B |
| September 05, 2024 | 15.32B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
9.501B
Minimum
Mar 16 2020
28.99B
Maximum
Sep 03 2021
19.37B
Average
20.19B
Median
Mar 17 2023
Enterprise Value Benchmarks
| Novo Nordisk AS | 472.39B |
| Ascendis Pharma AS | 7.975B |
| Galecto Inc | -10.60M |
| Evaxion Biotech AS | 5.018M |
| IO Biotech Inc | -36.84M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 186.57M |
| Revenue (Quarterly) | 816.44M |
| Total Expenses (Quarterly) | 504.16M |
| EPS Diluted (Quarterly) | 0.2919 |
| Gross Profit Margin (Quarterly) | 95.07% |
| Profit Margin (Quarterly) | 22.85% |
| Earnings Yield | 4.96% |
| Operating Earnings Yield | 6.83% |
| Normalized Earnings Yield | 5.607 |